Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

6.7%

2 terminated out of 30 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed with results

Key Signals

71% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (4)
P 1 (1)
P 2 (15)
P 3 (1)

Trial Status

Recruiting15
Not Yet Recruiting7
Completed5
Terminated2
Active Not Recruiting1

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT05286814Phase 2Recruiting

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT06777316Phase 1Active Not RecruitingPrimary

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

NCT07476651Not ApplicableRecruiting

Scout Dose of Resin Microspheres

NCT07479264CompletedPrimary

A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma

NCT07225452CompletedPrimary

An Exosomal miRNA-based Liquid Biopsy for ICC Detection

NCT07224737CompletedPrimary

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

NCT06859684Phase 2RecruitingPrimary

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

NCT06739252Phase 2TerminatedPrimary

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

NCT07353827Phase 2Not Yet RecruitingPrimary

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

NCT07337850Recruiting

Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers

NCT07328919Phase 3Not Yet RecruitingPrimary

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

NCT07304388Phase 2CompletedPrimary

HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC

NCT06735560Not ApplicableRecruiting

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN

NCT06925516Phase 2RecruitingPrimary

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

NCT07153783Not ApplicableCompleted

Interventional AI-Human Collaboration for Liver Tumor Diagnosis

NCT07208526Not ApplicableNot Yet RecruitingPrimary

A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST

NCT07176962Recruiting

A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening

NCT07161869Not Yet Recruiting

Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)

NCT07128290Phase 2Not Yet RecruitingPrimary

PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

NCT07070700Phase 2RecruitingPrimary

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Scroll to load more

Research Network

Activity Timeline